AST SpaceMobile stock tanks after flawed satellite launch by Blue Origin

AST SpaceMobile shares fell as much as 9% after BlueBird 7, launched on Blue Origin’s New Glenn rocket, was placed into a lower-than-planned orbit too low to sustain operations. The lost satellite will be covered by insurance, and the company still expects to launch satellites every one to two months in 2026 while targeting about 45 satellites in orbit by year-end. The setback raises questions about the New Glenn launch and pushed ASTS into negative territory year to date, though the stock remains up more than 270% over the past year.

Analysis

This is less about one satellite and more about how much execution slippage the market is willing to tolerate in a story priced for near-flawless constellation deployment. The stock’s recent rerating leaves it vulnerable to any proof that launch cadence, orbital insertion quality, or downstream commissioning is less deterministic than bulls assumed; in other words, the equity is trading like a manufacturing ramp, but the business still behaves like a high-variance space program.

The key second-order issue is confidence in the launch stack, not the insured hardware loss. Insurance limits direct P&L damage, but it does not insure schedule confidence, and schedule confidence is what supports the multiple. If deployment cadence slips even one quarter, the market is likely to compress forward EV/revenue assumptions more than the near-term cash impact would suggest, because the valuation depends on a narrow timing window for satellite count milestones and commercial readiness.

There is also a relative-value angle: if investors start assigning a higher probability to launch/orbit mishaps, they may punish ASTS more than launch providers or suppliers because ASTS bears the monetization risk while others can spread it across customers. That makes this a positioning event as much as a fundamental one; a 5-10% drawdown can extend if systematic holders de-risk from a momentum name that has already run hard over 12 months.

The contrarian view is that this may be more of a sequencing problem than a thesis breaker. A single failed orbit insertion is painful but not fatal if the company can still sustain a monthly-to-bimonthly cadence in 2026; for long-duration holders, the bigger question is whether today’s selloff creates a better entry into a business whose end-market remains structurally large. The market is likely pricing in a higher failure rate than the insurance-adjusted economics justify, which could make the move overdone if the next launch confirms process control.

Key Decisions for Investors

• Trim ASTS into strength on any intraday rebound; near-term upside is likely capped until the next successful deployment reduces execution uncertainty. Risk/reward favors selling rallies rather than chasing dips for now.
• For event-driven accounts, buy short-dated ASTS puts or put spreads into the next launch-related catalyst. The best asymmetry is a 2-6 week horizon where sentiment can deteriorate faster than fundamentals can recover.
• If you want to keep exposure, switch from outright long ASTS to a call spread structure 1-2 quarters out. That preserves upside if the cadence resumes, while limiting theta decay if the market continues to re-rate execution risk.
• Pair trade: long a launch/space infrastructure beneficiary with diversified revenue exposure against ASTS, to isolate execution risk rather than sector beta. The trade works best if the next 30-60 days bring more scrutiny to launch reliability.
• Add to ASTS only after a subsequent successful orbit insertion or cadence confirmation; use that event as the signal that the market has over-discounted a one-off operational miss.